N-(6-Nitrobenzo[d][1,3]dioxol-5-yl)acetamide | 81864-14-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: N-(6-Nitrobenzo[d][1,3]dioxol-5-yl)acetamide
• 英文别名: N-(6-nitro-1,3-benzodioxol-5-yl)acetamide；N-(6-nitro-benzo[1,3]dioxol-5-yl)-acetamide；N-(6-Nitro-benzo[1,3]dioxol-5-yl)-acetamid；5-acetamino-6-nitro-1,3-benzodioxole
• CAS: 81864-14-4
• 化学式: C₉H₈N₂O₅
• 分子量: 224.173
• InChiKey: JVGRDSBPPKBVBI-UHFFFAOYSA-N

物化性质

• 熔点：
  209 °C
• 沸点：
  440.6±45.0 °C(Predicted)
• 密度：
  1.540±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  93.4
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2932999099

反应信息

• 作为反应物：
  描述：

  N-(6-Nitrobenzo[d][1,3]dioxol-5-yl)acetamide 在 sodium methylate 作用下， 以 甲醇 、 二氯甲烷 、 溶剂黄146 为溶剂， 生成 6-硝基-1,3-苯并二氧代l-5-胺
  参考文献：
  名称：

  Imidazole derivatives

  摘要：

  Tricyclic imidazole derivatives of the formula ##STR1## wherein R.sup.1 is 2-pyridyl optionally substituted by lower alkyl or lower alkoxy, n is the integer 0 or 1, R.sup.2 is hydrogen or lower alkyl, R.sup.3 and R.sup.4, independently, are hydrogen or lower alkyl, A is a group of the formula ##STR2## m is the integer 2 or 3, R.sup.5, R.sup.6, R.sup.7 and R.sup.8, independently, are hydrogen or lower alkyl, and R.sup.9 is hydrogen and R.sup.10 is hydrogen or lower alkyl or R.sup.9 and R.sup.10 taken together are oxo, provided that at least one of R.sup.3 and R.sup.4 is lower alkyl when A is a group of the formula --CH.dbd.CH--CH.dbd.CH-- or --(CH.sub.2).sub.4 --, and their pharmaceutically acceptable acid addition salts. The compounds of formula I inhibit gastric acid secretion and prevent the formation of gastric ulcers.

  公开号：

  US04435406A1
• 作为产物：
  描述：

  3,4-亚甲基二氧基乙酰苯胺 在 硝酸 作用下， 以 溶剂黄146 为溶剂， 生成 N-(6-Nitrobenzo[d][1,3]dioxol-5-yl)acetamide
  参考文献：
  名称：

  Imidazole derivatives

  摘要：

  Tricyclic imidazole derivatives of the formula ##STR1## wherein R.sup.1 is 2-pyridyl optionally substituted by lower alkyl or lower alkoxy, n is the integer 0 or 1, R.sup.2 is hydrogen or lower alkyl, R.sup.3 and R.sup.4, independently, are hydrogen or lower alkyl, A is a group of the formula ##STR2## m is the integer 2 or 3, R.sup.5, R.sup.6, R.sup.7 and R.sup.8, independently, are hydrogen or lower alkyl, and R.sup.9 is hydrogen and R.sup.10 is hydrogen or lower alkyl or R.sup.9 and R.sup.10 taken together are oxo, provided that at least one of R.sup.3 and R.sup.4 is lower alkyl when A is a group of the formula --CH.dbd.CH--CH.dbd.CH-- or --(CH.sub.2).sub.4 --, and their pharmaceutically acceptable acid addition salts. The compounds of formula I inhibit gastric acid secretion and prevent the formation of gastric ulcers.

  公开号：

  US04435406A1

文献信息

• Imidazole derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US04435406A1

  公开（公告）日：1984-03-06

  Tricyclic imidazole derivatives of the formula ##STR1## wherein R.sup.1 is 2-pyridyl optionally substituted by lower alkyl or lower alkoxy, n is the integer 0 or 1, R.sup.2 is hydrogen or lower alkyl, R.sup.3 and R.sup.4, independently, are hydrogen or lower alkyl, A is a group of the formula ##STR2## m is the integer 2 or 3, R.sup.5, R.sup.6, R.sup.7 and R.sup.8, independently, are hydrogen or lower alkyl, and R.sup.9 is hydrogen and R.sup.10 is hydrogen or lower alkyl or R.sup.9 and R.sup.10 taken together are oxo, provided that at least one of R.sup.3 and R.sup.4 is lower alkyl when A is a group of the formula --CH.dbd.CH--CH.dbd.CH-- or --(CH.sub.2).sub.4 --, and their pharmaceutically acceptable acid addition salts. The compounds of formula I inhibit gastric acid secretion and prevent the formation of gastric ulcers.

  Tricyclic imidazole derivatives of the formula ##STR1## wherein R.sup.1 is 2-pyridyl optionally substituted by lower alkyl or lower alkoxy, n is the integer 0 or 1, R.sup.2 is hydrogen or lower alkyl, R.sup.3 and R.sup.4, independently, are hydrogen or lower alkyl, A is a group of the formula ##STR2## m is the integer 2 or 3, R.sup.5, R.sup.6, R.sup.7 and R.sup.8, independently, are hydrogen or lower alkyl, and R.sup.9 is hydrogen and R.sup.10 is hydrogen or lower alkyl or R.sup.9 and R.sup.10 taken together are oxo, provided that at least one of R.sup.3 and R.sup.4 is lower alkyl when A is a group of the formula --CH.dbd.CH--CH.dbd.CH-- or --(CH.sub.2).sub.4 --, and their pharmaceutically acceptable acid addition salts. The compounds of formula I inhibit gastric acid secretion and prevent the formation of gastric ulcers.
• 신규한 디플루오로아세트산 유도체 화합물 및 이를 포함한 조성물
  申请人：Pusan National University Industry-University Cooperation Foundation 부산대학교 산학협력단(220040044843) BRN ▼621-82-06530

  公开号：KR20200011270A

  公开（公告）日：2020-02-03

  본 발명은 신규한 디플루오로아세트산 유도체 화합물 및 이를 포함하는 다양한 용도의 조성물에 관한 것으로, 상기 디플루오로아세트산 유도체 화합물은 PPARα, β 또는 γ 중 어느 하나를 활성화시키는 어고니스트로서 작용할 수 있을 뿐만 아니라, 이중 효능 또는 삼중 효능을 나타낼 수 있는 바, 따라서 PPARs이 관여하는 대사성 질환을 보다 효과적으로 예방, 개선 내지 치료할 수 있고, 더 나아가 미백 및 주름 개선 활성, 항염증 및 항산화 효과까지 나타낼 수 있으므로, 다양한 조성물로서 유용하게 활용될 수 있다.

  本发明涉及一种新型的二氟乙酸衍生物化合物及包含它的各种用途的组合物，所述二氟乙酸衍生物化合物可以作为激活PPARα、β或γ中任一种的激动剂，不仅可以发挥单一作用，还可以表现出双重或三重效应，因此可以更有效地预防、改善或治疗与PPARs相关的代谢性疾病，同时还表现出美白和减少皱纹的活性，具有抗炎和抗氧化效果，因此可以作为各种组合物中有用的成分。
• Pyridyl methyl thio or sulfinyl indeno(5,6-d)imidazoles
  申请人：Hoffmann-La Roche Inc.

  公开号：US04554280A1

  公开（公告）日：1985-11-19

  Tricyclic imidazole derivatives of the formula ##STR1## wherein R.sup.1 is 2-pyridyl optionally substituted by lower alkyl or lower alkoxy, n is the integer 0 or 1, R.sup.2 is hydrogen or lower alkyl, R.sup.3 and R.sup.4, independently, are hydrogen or lower alkyl, A is a group of the formula ##STR2## m is the integer 2 or 3, R.sup.5, R.sup.6, R.sup.7 and R.sup.8, independently, are hydrogen or lower alkyl, and R.sup.9 is hydrogen and R.sup.10 is hydrogen or lower alkyl or R.sup.9 and R.sup.10 taken together are oxo, provided that at least one of R.sup.3 and R.sup.4 is lower alkyl when A is a group of the formula --CH.dbd.CH--CH.dbd.CH-- or --(CH.sub.2).sub.4 --, and their pharmaceutically acceptable acid addition salts. The compounds of formula I inhibit gastric acid secretion and prevent the formation of gastric ulcers.

  公式为 ##STR1## 的三环咪唑衍生物，其中R.sup.1是2-吡啶基，可选择地被低烷基或低烷氧基取代，n是整数0或1，R.sup.2是氢或低烷基，R.sup.3和R.sup.4独立地是氢或低烷基，A是公式 ##STR2## 的基团，m是整数2或3，R.sup.5，R.sup.6，R.sup.7和R.sup.8独立地是氢或低烷基，R.sup.9是氢，R.sup.10是氢或低烷基或R.sup.9和R.sup.10一起是氧代，但当A是公式--CH.dbd.CH--CH.dbd.CH--或--（CH.sub.2）.sub.4--的基团时，至少R.sup.3和R.sup.4中的一个是低烷基，它们的药学上可接受的酸盐。公式I的化合物抑制胃酸分泌并预防胃溃疡的形成。
• Tetrahydro-naphth (2.3-d) imidazole derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US04599347A1

  公开（公告）日：1986-07-08

  Tricyclic imidazole derivatives of the formula ##STR1## wherein R.sup.1 is 2-pyridyl optionally substituted by lower alkyl or lower alkoxy, n is the integer 0 to 1, R.sup.2 is hydrogen or lower alkyl, R.sup.3 and R.sup.4, independently, are hydrogen or lower alkyl, A is a group of the formula ##STR2## m is the integer 2 or 3, R.sup.5, R.sup.6, R.sup.7 and R.sup.8, independently, are hydrogen or lower alkyl, and R.sup.9 is hydrogen and R.sup.10 is hydrogen or lower alkyl or R.sup.9 and R.sup.10 taken together are oxo, provided that at least one of R.sup.3 and R.sup.4 is lower alkyl when A is a group of the formula --CH.dbd.CH--CH.dbd.CH-- or --(CH.sub.2).sub.4 --, and their pharmaceutically acceptable acid addition salts. The compounds of formula I inhibit gastric acid secretion and prevent the formation of gastric ulcers.

  公式为##STR1##的三环咪唑衍生物，其中R.sup.1是2-吡啶基，可选择性地被低烷基或低烷氧基取代，n为整数0至1，R.sup.2为氢或低烷基，R.sup.3和R.sup.4独立地为氢或低烷基，A为公式##STR2##的基团，m为整数2或3，R.sup.5、R.sup.6、R.sup.7和R.sup.8独立地为氢或低烷基，R.sup.9为氢，R.sup.10为氢或低烷基，或R.sup.9和R.sup.10共同为氧代，但当A为--CH.dbd.CH--CH.dbd.CH--或--(CH.sub.2).sub.4--的基团时，R.sup.3和R.sup.4中至少有一个为低烷基。这些公式I的化合物能够抑制胃酸分泌并预防胃溃疡的形成，其药物可接受的酸盐。
• Tricyclic 1,2,4-triazine oxides and compositions for therapeutic use in cancer treatments
  申请人：Auckland Uniservices Limited

  公开号：US07989451B2

  公开（公告）日：2011-08-02

  The invention relates to novel tricyclic 1,2,4-triazine-1-oxides and novel tricyclic 1,2,4-triazine-1,4-dioxides of formula I and to related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.

  本发明涉及新型三环1,2,4-三嗪-1-氧化物和新型三环1,2,4-三嗪-1,4-二氧化物的公式I以及相关类似物，涉及它们的制备，以及它们作为缺氧选择性药物和放射增敏剂用于癌症治疗，无论是单独使用还是与放射治疗和/或其他抗癌药物联合使用。